U.S. Tobacco Stock News

Douglas Elliman slipped 0.6% to US$1.78 after its second quarter report, a muted move for a stock tied to luxury housing sentiment. The headline is not the price; it is the sharp improvement in the income statement. Revenue was US$283.4m and the quarterly loss narrowed to US$2.7m. For a brokerage that only recently turned profitable on a trailing basis, that combination turns today’s dip into a sentiment check rather than a clear verdict. The rest of the report shows how fragile or durable...

In the second quarter of 2026, Upbound Group, Inc. reported sales of US$903.7 million, revenue of US$1.16 billion, and net income of US$21.58 million, with basic earnings per share from continuing operations of US$0.37, all modestly higher than a year earlier. The company also narrowed its full-year 2026 consolidated revenue outlook to US$4.70–US$4.85 billion and issued third-quarter revenue guidance of US$1.05–US$1.15 billion, giving investors a clearer view of expected scale and earnings...

A surprise loss of 23,000 US jobs in July and softer wage growth has put resilience back in the spotlight. Healthcare giants in areas such as pharmaceuticals and medical equipment are often watched closely when the broader economy looks less certain, because demand for many treatments can remain steady. This article reveals 3 large healthcare stocks from our screener that appear well placed against this backdrop. The three stocks highlighted below are just a sample from this theme, with the...

Regulatory milestone puts focus on GRAIL stock GRAIL (GRAL) is in the spotlight after the FDA scheduled a September 23, 2026 advisory committee meeting to review the Premarket Approval application for its Galleri multi cancer early detection blood test. See our latest analysis for GRAIL. The FDA panel date has come alongside GRAIL’s recent Q2 update and a sharp 1 day share price return of 9.59%, even though the year to date share price return is down 21.82%. Over the past year, the total...

Biglari Holdings stock barely flinched after earnings, easing just 0.3%, yet the headline result was anything but quiet. A swing to basic earnings per share of US$158.17 for the quarter, alongside net income of US$39.93 million, marks a sharp break from the recent run of losses. The market still treats Biglari as an unprofitable story with stretched valuation, which sets up a sentiment clash between the trailing weakness and a powerful single quarter of profitability. Is Biglari Holdings now...

In late July 2026, Align Technology reported second-quarter 2026 results showing sales rising to US$1,056.19 million year-on-year, issued softer sequential revenue guidance for the third quarter, and outlined the impact of one-time restructuring, depreciation, and legal charges on its GAAP operating margin outlook. At the same time, after discussions with Elliott Investment Management, Align committed to appoint three new independent directors, launched a comprehensive strategic and...

With the Iran war disrupting the Strait of Hormuz, inflation staying stubbornly high and rate hikes still on the table, many investors are questioning how much risk is really baked into today’s lofty valuations. Periods like this can punish fragile business models but also reveal sturdier ones. This article focuses on 3 large cap value stocks that screens suggest are more exposed to these shocks, and explains what that could mean for your portfolio decisions. The three stocks below are only a...

FIGS stock has delivered a very strong 129.3% return over the past year, yet its valuation checks still suggest the shares are not an obvious bargain. Recent optimism around growth and profitability now sits alongside a low overall value score and an assessment that the stock screens as overvalued on market multiples. The 129.3% one year return signals that expectations around FIGS have shifted quickly and that recent buyers are paying a much higher price than they were a year ago. Stronger...

In the second quarter of 2026, Biogen Inc. reported revenue of US$2,736.0 million, up from US$2,645.5 million a year earlier, while net income fell to US$97.5 million and diluted earnings per share from continuing operations declined to US$0.66 from US$4.33. Despite higher sales and revenue, Biogen’s earnings compressed significantly, even as its newer therapies outpaced its legacy multiple sclerosis portfolio and the Apellis acquisition expanded its growth product lineup. We’ll now examine...

TOMS Capital’s no confidence campaign against Voya Financial (VOYA) has moved into a new phase, with a definitive proxy filing and an open letter challenging the board’s decisions, recent execution, and approach to potential third party interest. See our latest analysis for Voya Financial. At a share price of US$101.40, Voya Financial has delivered a 26.54% 90 day share price return and a 46.36% 1 year total shareholder return. This suggests recent momentum has been strong despite the fresh...

D.R. Horton stock has delivered a 62.8% gain over the past five years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples currently point to the shares trading below what those frameworks suggest as fair. Over the last five years, D.R. Horton has returned 62.8%, which means long term holders have already seen solid value creation even before considering today’s valuation signals. Market expectations for future housing demand and construction activity can...

ANI Pharmaceuticals just took a 5.3% hit in a single session, yet the earnings story looks more like growing pains than a broken thesis. You have a stock that came into the print soft over the past month, then sold off again right after reporting adjusted earnings per share of US$2.21 on revenue of US$266.0m. The real swing factor is profit quality. Investors appear to be wrestling with how much of the recent profitability and trailing US$259.6m of adjusted EBITDA reflects repeatable rare...

Embecta entered this quarter wearing the label of a deeply discounted diabetes device stock, with a single digit P/E and significant balance sheet questions. The market lifted the share price 26% to US$4.42 in the first session after earnings. The move reflects one headline takeaway: the business reported a sharp rebound in both revenue and profit, with Q3 sales of US$271.7m and net income of US$21.1m after a loss in Q2. For a company under pressure over debt and cash generation, that...

How PayPal's Latest Earnings Set the Stage for Investors PayPal Holdings (PYPL) just reported second quarter 2026 results, with sales of US$8.68b and net income of US$1.10b, giving investors a mixed update on growth and profitability. Sales for the first half of 2026 reached US$17.04b, while net income for the same period came in at US$2.22b. Earnings per share from continuing operations were lower than a year ago on both a basic and diluted basis. At the same time, PayPal Holdings (PYPL)...

In late July 2026, Laureate Education, Inc. reported second-quarter sales of US$615.86 million and net income of US$137.1 million, alongside higher first-half earnings and an updated full-year 2026 revenue outlook of US$1.92 billion to US$1.93 billion, implying 13% as-reported growth. At the same time, Laureate expanded its share repurchase effort, having already bought back 13,863,000 shares for US$399.61 million and adding a further US$250 million authorization, highlighting management’s...

Under Armour stock fell about 4.5% to US$6.11 in the first trading session after its Q1 2027 report, adding fresh pressure to an already weak one month stretch. At first glance the reaction looks harsh for a company that just posted a small profit and stronger than expected adjusted operating income. The real headline is not the quarter. It is the decision to cut full year revenue guidance to a mid single digit decline while still holding the US$140 million to US$160 million adjusted...

Praxis Precision Medicines (NasdaqGS: PRAX) reported new clinical and regulatory milestones across its central nervous system pipeline, including progress on several drug candidates. The company received FDA Breakthrough Therapy designation for Elsunersen, its investigational treatment for neurological disorders. Praxis expanded its CNS program through collaborations and licensing agreements with partners including RogCon Inc. and Ionis Pharmaceuticals. This kind of pipeline and partnership...

Century Aluminum stock has delivered a very large 3 year gain, yet it still screens as undervalued on Simply Wall St’s valuation checks. This sets up a clear question about how much upside may be left in the current price of US$51.23. Over the past 3 years the share price has risen by a very large amount, which puts more focus on whether recent returns can be supported by fundamentals. The completion of production restarts at Mt. Holly and Grundartangi can support revenue and earnings...

Tariff power that stretches up to 100% on key Russian energy importers puts trade relationships, inflation, and company cost structures back in the spotlight. That kind of policy shock can quickly separate potential winners from stocks that may struggle. This article walks through three U.S. utilities and infrastructure stocks that appear positioned on the positive side of this story and explains why their businesses could matter for your watchlist now. The stocks covered below are just a...

BridgeBio Pharma (BBIO) has drawn fresh attention after recent share price moves, with the stock closing at $84.48 on 6 August 2026. Investors are weighing this level against the company’s longer term return profile. See our latest analysis for BridgeBio Pharma. The latest move in BridgeBio Pharma’s share price builds on a 30.61% 90 day share price return and an 81.37% 1 year total shareholder return. However, the 30 day share price return of 1.64% shows some cooling in the very short...

Edison International recently reported its second-quarter 2026 results, with sales of US$4,357 million versus US$4,543 million a year earlier, while net income increased to US$534 million and diluted EPS from continuing operations rose to US$1.38 from US$0.89. Despite higher quarterly earnings, the company’s six-month net income fell to US$1.07 billion from US$1.78 billion and it lowered its 2026 basic EPS guidance to US$5.70–US$6.00 from US$5.86–US$6.16, signaling a more cautious full-year...

Zillow Group (NasdaqGS:ZG) has announced a series of executive leadership changes, including a new Chief Legal and Policy Officer. Cassandra Knight, previously Vice President, Litigation and Discovery at Google, has been appointed Chief Legal and Policy Officer at Zillow Group. Jeremy Hofmann's responsibilities have been expanded to COO and CFO, with additional leadership promotions across the company. These leadership moves at Zillow Group highlight a wider shift in how real estate and...

UWM Holdings Corporation recently reported a Q2 2026 net loss of US$80.59 million, reversing from net income of US$22.91 million a year earlier, and filed an omnibus shelf registration covering multiple securities classes, while also suspending its dividend and raising new capital amid a pressured mortgage market. This combination of weaker profitability, dividend suspension, and added capital-raising flexibility signals a renewed focus on balance sheet strength and financial resilience for...

After a strong three-year run that has seen Gates Industrial stock return about 139%, the current share price now sits against an intrinsic value estimate that still points to upside, while the broader valuation checks paint more of a mixed picture. The roughly 139% return over three years puts Gates Industrial in clear outperformer territory, so the key issue now is whether the current price still leaves room for further value. Recent earnings strength and upgraded expectations can support...